The pharmacological treatment of acute hereditary angioedema (HAE) attacks targets the kallikrein-kinin cascade at two points: the bradykinin B2 receptor (icatibant) and plasma kallikrein itself (ecallantide). Both agents interrupt the pathological bradykinin-mediated vascular permeability that causes the subcutaneous and submucosal edema of HAE. Their distinct mechanisms, routes of administration, and approval status in the United States and Europe reflect different approaches to the same therapeutic problem.
Icatibant (Firazyr) is a synthetic decapeptide and competitive antagonist at the bradykinin B2 receptor with high receptor selectivity, minimal B1 receptor activity, and no agonist properties. Its amino acid sequence is a modified bradykinin analog in which five of the ten residues are non-natural amino acids specifically introduced to confer protease resistance, a critical pharmacokinetic requirement given that natural bradykinin itself is degraded within seconds in plasma. Icatibant is administered subcutaneously at a dose of 30 mg; the subcutaneous route delivers drug directly into the interstitial compartment, which is clinically appropriate because the target tissue for HAE attacks is the subendothelial space where bradykinin exerts its permeability effects. After subcutaneous injection, peak plasma concentrations are achieved at approximately 0.75–1 hour, with a plasma half-life of approximately 1–2 hours. Despite the short half-life, clinical duration of effect is 6–8 hours, attributed to sustained tissue concentrations and the persistence of local bradykinin generation at the attack site. Patients are permitted to self-administer icatibant at home following training, which is an important practical advantage in a condition where attacks can be geographically remote from medical facilities.5
The clinical efficacy of icatibant was established in the FAST-1 and FAST-3 randomized controlled trials. FAST-3 showed icatibant reduced time to onset of symptom relief versus placebo by approximately 2 hours (median 2.0 hours versus 19.8 hours for placebo) across cutaneous, abdominal, and laryngeal attacks, with a favorable safety profile.5 A second dose can be administered if symptoms recur or are incompletely controlled, with a third dose available if needed, each separated by at least 6 hours. Icatibant is approved for acute HAE attacks in adults aged 18 and older (European Medicines Agency (EMA) approval), and for patients aged 12 and older in the United States (Food and Drug Administration (FDA) approval). The most common adverse effect is injection site reactions (erythema, edema, burning at the injection site), which are common but mild and self-resolving. Icatibant has been investigated as off-label therapy for acute ACEI-induced angioedema, with mixed results from small trials suggesting a modest benefit in reducing attack duration, though robust phase III evidence in this indication is lacking.1
Ecallantide (Kalbitor) is a recombinant 60-amino-acid protein that acts as a potent, highly selective competitive inhibitor of plasma kallikrein, the serine protease that cleaves high-molecular-weight kininogen (HMWK) to generate bradykinin. By blocking kallikrein at the step upstream of bradykinin generation, ecallantide prevents the formation of the mediator rather than blocking its receptor. Ecallantide is administered subcutaneously at a dose of 30 mg given as three separate 10 mg injections at different subcutaneous sites during the same treatment session; this divided administration approach was adopted because injection site reactions are common with concentrated bolus delivery. Its plasma half-life is approximately 2 hours. Ecallantide is FDA-approved in the United States for acute HAE attacks in patients aged 12 and older; it is not approved in Europe. A significant safety concern is anaphylaxis, which occurs in approximately 3.9% of patients, attributed to the development of anti-ecallantide antibodies in some recipients and to direct mast cell activation by the protein; accordingly, ecallantide must be administered in a healthcare setting with the ability to manage anaphylaxis, unlike icatibant which can be self-administered.2
A practical comparison of icatibant and ecallantide reveals complementary profiles suited to different clinical contexts. Icatibant acts at the B2 receptor and therefore blocks all bradykinin already formed, regardless of how it was generated; this makes it theoretically effective even when the kallikrein system is already maximally activated and bradykinin levels are high. Ecallantide acts upstream and prevents new bradykinin generation, which may have a slower onset of clinical effect if bradykinin already present in tissues continues to drive symptoms during the interval before its degradation. Both agents have demonstrated efficacy for abdominal and cutaneous attacks; laryngeal attacks, which carry the highest mortality risk, are managed with the same agents but any laryngeal HAE attack should prompt immediate medical supervision and preparation for airway management regardless of the agent selected. Neither agent has demonstrated clear superiority over the other in direct comparative trials; the choice between them is often driven by local approval status, institutional availability, and patient preference for self-administration.1,2
HAE attacks frequently begin in community settings, with onset to peak severity occurring within hours. The ability to self-administer icatibant subcutaneously at home, following standardized training, dramatically reduces the time from attack onset to treatment initiation compared to travel to an emergency department for IV C1-INH or ecallantide administration. Real-world registry data consistently show that shorter time to treatment correlates with faster attack resolution and reduced severity. All patients with a confirmed HAE diagnosis who are capable of self-injection should have icatibant available as rescue therapy regardless of what prophylactic agent they are receiving. Emergency department physicians encountering HAE patients should inquire whether the patient carries icatibant and allow them to administer it, rather than defaulting to less effective non-specific treatments such as antihistamines and corticosteroids.
C1 inhibitor (C1-INH) concentrates replace the deficient or dysfunctional serpin that is the root cause of HAE types I and II, restoring physiological control of the kallikrein-kinin and complement contact activation systems simultaneously. Lanadelumab (Takhzyro) takes a distinct prophylactic approach: a human monoclonal antibody that binds and inhibits plasma kallikrein, preventing bradykinin generation before attacks begin. Together these agents constitute the current standard for both acute management and long-term attack prevention in HAE.
Plasma-derived C1-INH concentrates (pdC1-INH) are purified from pooled human plasma and include Berinert (CSL Behring) and Cinryze (Shire/Takeda). Both products contain functional C1-INH at concentrations sufficient to restore plasma C1-INH levels into or above the normal range after intravenous administration. Berinert is FDA-approved for acute attack treatment in adults and children at a dose of 20 IU/kg intravenously; its onset of action in clinical trials was median 30–60 minutes to beginning of symptom relief, reflecting the time required to redistribute into the tissue compartment and restore kallikrein inhibition. Cinryze is approved for both acute attack treatment and routine prophylaxis in adults and adolescents; when used prophylactically, it is administered at 1000 IU intravenously every 3–4 days to maintain C1-INH activity above the threshold associated with attack prevention. Both products undergo viral inactivation steps during manufacturing to reduce transfusion-transmitted infection risk, and adverse events are generally mild; anaphylaxis is rare but possible, particularly in patients with antibodies to specific plasma proteins. The requirement for intravenous access limits home use compared to subcutaneous options, though subcutaneous formulations of C1-INH have entered clinical use and are discussed below.3
Recombinant human C1-INH (rhC1-INH, Ruconest/Conestat alfa) is produced in the milk of transgenic rabbits and provides a non-plasma-derived alternative for patients with concerns about plasma products or who have had prior adverse reactions. It is approved for acute HAE attack treatment in adults at a dose of 50 IU/kg intravenously (maximum 4200 IU). Its mechanism is identical to endogenous C1-INH and plasma-derived products, but its shorter half-life (approximately 3 hours versus 30–40 hours for pdC1-INH) means it is not suitable for prophylaxis at currently approved doses. Patients with known rabbit allergy should not receive Ruconest. A subcutaneous formulation of plasma-derived C1-INH (HAEGARDA, CSL Behring) is approved for routine prophylaxis, administered at 60 IU/kg subcutaneously twice weekly by patient self-injection; this route avoids the need for intravenous access and permits home-based prophylaxis with a significantly improved quality of life compared to IV prophylaxis schedules.3
Lanadelumab (Takhzyro) is a fully human IgG1 kappa monoclonal antibody that binds to and inhibits plasma kallikrein, the enzyme that generates bradykinin from HMWK. Unlike C1-INH concentrates, which restore a physiological inhibitor, lanadelumab is a pharmacological inhibitor of kallikrein activity that does not affect complement pathway activity or other C1-INH-regulated systems. It is approved for HAE prophylaxis in adults and pediatric patients aged 12 and older, administered subcutaneously at 300 mg every 2 weeks for the first six months, with potential extension to every 4 weeks in patients who are well-controlled and attack-free for at least 6 months. The HELP trial, the pivotal phase III randomized controlled trial, demonstrated that lanadelumab at 300 mg every 2 weeks reduced HAE attack rate by approximately 87% versus placebo, with 44% of patients achieving complete attack freedom during the treatment period. Lanadelumab's half-life of approximately 23 days is consistent with typical IgG1 pharmacokinetics and supports its prolonged dosing interval. Adverse effects are predominantly injection site reactions; no significant immunogenicity has been observed in phase III trials, and no drug-drug interactions have been identified because lanadelumab does not affect CYP enzymes or drug transporters.4
Both lanadelumab and prophylactic C1-INH concentrates (Cinryze IV or HAEGARDA SC) reduce HAE attack frequency substantially, but they differ in mechanism, route, dosing frequency, and patient selection considerations. Lanadelumab acts by inhibiting kallikrein activity pharmacologically and does not correct the underlying C1-INH deficiency; C1-INH concentrates restore the missing protein and normalize the entire contact activation cascade, including complement. In practice, patients who have breakthrough attacks on one prophylactic regimen can often be switched to the other with benefit. The availability of subcutaneous self-administered options for both lanadelumab and HAEGARDA has significantly improved patient adherence and quality of life compared to IV prophylaxis. Both are appropriate first-line prophylactic choices; patient preference for injection frequency, self-administration capability, and insurance access typically determine selection.
Comprehensive HAE management integrates three strategic domains: acute attack treatment (discussed in Section 1), long-term prophylaxis to reduce attack frequency (Section 2), and trigger identification and avoidance to reduce the frequency of attacks requiring pharmacological intervention. A fourth domain, emerging and pipeline therapies, is reshaping expectations for attack prevention and potential disease modification in HAE.
Short-term prophylaxis (STP) is given before procedures, surgeries, or situations expected to trigger HAE attacks. Surgical trauma, endotracheal intubation, dental procedures, and emotional stress are recognized HAE triggers, and patients undergoing elective procedures should receive prophylaxis regardless of baseline attack frequency because the surgical stress response reliably activates the contact activation system. The recommended STP for major procedures in patients with access to pdC1-INH is 1000 IU IV of Berinert or Cinryze administered 1–6 hours before the procedure. In patients without access to C1-INH concentrate, fresh frozen plasma (FFP) is an alternative because it contains functional C1-INH, factor XII, and other contact activation proteins; however, FFP can paradoxically worsen HAE attacks in some patients because it also contains HMWK (the bradykinin precursor), and this risk means FFP is considered a second-line option. Attenuated androgens (danazol) can be used for STP when given for 5–7 days before the procedure; they increase hepatic synthesis of C1-INH and other contact system proteins. For emergency procedures, IV C1-INH is preferred because oral androgens require days of dosing to achieve effect.5
Attenuated androgens, primarily danazol and stanozolol, were the mainstay of long-term HAE prophylaxis before the availability of modern biologic agents. Their mechanism is upregulation of hepatic C1-INH gene expression, increasing plasma C1-INH levels and activity into or above the normal range in responsive patients. Danazol is typically initiated at 200–600 mg daily and titrated to the lowest effective dose for attack prevention. Adverse effects are dose-dependent and significant: virilization (hirsutism, clitoral hypertrophy, voice deepening) in women, hepatotoxicity (transaminase elevation, peliosis hepatis, hepatocellular carcinoma with long-term use), lipid abnormalities, and erythrocytosis. Danazol is absolutely contraindicated in pregnancy (androgenic teratogenicity), in children (premature epiphyseal closure and virilization), and in patients with active liver disease. Given the availability of safer, more effective modern prophylactic agents, danazol is now reserved for patients who have failed or cannot access biologic prophylaxis, or who have achieved decades of stable disease control on low-dose danazol and prefer not to change therapy. Tranexamic acid, an antifibrinolytic agent that reduces plasmin-mediated factor XII activation, has been used as a milder prophylactic alternative with a better safety profile than danazol but inferior efficacy.5
Attack trigger identification and avoidance is a non-pharmacological cornerstone of HAE management. The most consistently identified triggers are emotional stress, physical trauma (including minor trauma such as dental work), estrogen exposure (oral contraceptives, hormone replacement therapy, pregnancy), infections (particularly upper respiratory tract infections), and the angiotensin-converting enzyme inhibitors discussed in Module 3. Estrogen exposure is a particularly important trigger because estrogen upregulates HMWK gene expression and downregulates C1-INH synthesis, both of which promote bradykinin generation. Women of reproductive age with HAE should avoid combined oral contraceptives containing ethinylestradiol; progestin-only contraceptives are generally tolerated. Pregnancy in HAE patients requires specialist multidisciplinary management: attacks typically worsen in the second and third trimesters, estrogen levels rise progressively throughout pregnancy, and many HAE medications (danazol, tranexamic acid) are contraindicated in pregnancy. C1-INH concentrates are safe in pregnancy and are the treatment of choice for both prophylaxis and acute attacks in pregnant HAE patients.3
Emerging therapies in HAE include donidalorsen (KVD900), an oral small-molecule plasma kallikrein inhibitor that can be taken at the onset of an HAE attack, offering a needle-free alternative to injectable acute treatments. Phase III trial results for donidalorsen have demonstrated efficacy comparable to injectable agents with a rapid oral onset, potentially transforming the acute treatment landscape for patients who are averse to self-injection. Garadacimab is an anti-factor XIIa monoclonal antibody that blocks the trigger of the contact activation cascade upstream of kallikrein; phase III data show robust attack rate reduction with monthly subcutaneous dosing. Fitusiran, a subcutaneously administered RNA interference (RNAi) therapy targeting antithrombin, is approved for hemophilia but has been investigated in HAE given the overlap between coagulation and contact activation systems. Gene therapy approaches using AAV vectors to deliver functional C1-INH transgenes are in early clinical development and represent a potential curative strategy.6
HAE type III is a distinct form of hereditary angioedema characterized by normal C1-INH levels and function, in which attacks are predominantly triggered by estrogen exposure. The molecular basis in many type III patients is a gain-of-function mutation in factor XII (Hageman factor) that renders it susceptible to activation by estrogen-induced conformational changes or plasma contact, producing unregulated kallikrein activation and bradykinin generation. Type III HAE disproportionately affects women and may first present during pregnancy or with initiation of estrogen-containing contraceptives. Diagnostic confusion with histamine-mediated allergic angioedema is common because standard complement studies (C1-INH level and function, C4) are normal. Management emphasizes strict estrogen avoidance and, when acute treatment is needed, the same agents used for types I and II (icatibant, C1-INH, ecallantide) on the basis that bradykinin is the final common mediator.
Sacubitril-valsartan (Entresto) represents a pharmacological advance in heart failure management through a mechanism that deliberately amplifies natriuretic peptide signaling, but that same mechanism also raises bradykinin levels through a pathway independent of ACE inhibition. Understanding the bradykinin pharmacology of neprilysin inhibition is essential for safe prescribing of sacubitril-valsartan and for managing the angioedema risk that is its most serious adverse effect.
Neprilysin (neutral endopeptidase 24.11, also designated CD10 or enkephalinase) is a zinc metallopeptidase expressed on the cell surface of many tissues including the kidney, lung, heart, and vascular endothelium. Its principal substrates relevant to cardiovascular pharmacology are the natriuretic peptides: atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), which promote natriuresis, vasodilation, and anti-fibrotic effects in the kidney and heart. In heart failure, endogenous natriuretic peptide levels are elevated as a compensatory response to cardiac chamber dilatation, but this response is attenuated because neprilysin activity also increases in proportion to the chronic neurohormonal activation of heart failure. Sacubitril, a prodrug converted to its active form LBQ657 in vivo, inhibits neprilysin and thereby increases circulating ANP and BNP, potentiating natriuresis, vasodilation, and cardioprotection. The PARADIGM-HF trial demonstrated that sacubitril-valsartan reduced cardiovascular death and heart failure hospitalization by 20% relative to enalapril in patients with heart failure with reduced ejection fraction (HFrEF), establishing it as a foundational therapy in this condition.7
Bradykinin is also a neprilysin substrate, and its degradation by neprilysin contributes to the normal clearance of bradykinin in plasma and tissues alongside ACE (kininase II) and carboxypeptidase N. When neprilysin is inhibited by sacubitril, bradykinin degradation is impaired through this additional enzymatic route, raising tissue bradykinin levels. This effect is additive to any concurrent ACE inhibition: when both ACE and neprilysin are inhibited simultaneously, two of the three principal bradykinin-clearing mechanisms are blocked, producing a substantially greater elevation in tissue bradykinin than either inhibitor alone. This pharmacodynamic interaction is the mechanistic basis for the absolute contraindication of sacubitril-valsartan within 36 hours of ACEI use and the requirement for a washout period when transitioning between these drug classes. Of note, sacubitril-valsartan contains an ARB (valsartan) rather than an ACEI, meaning it does not inhibit ACE directly; the bradykinin elevation from sacubitril alone is more modest than with sacubitril plus ACEI, and the rate of angioedema in PARADIGM-HF was low (0.45% versus 0.24% with enalapril) though not zero.7,8
The angioedema risk associated with sacubitril-valsartan is most concentrated in three groups: patients with prior ACEI-induced angioedema (in whom sacubitril-valsartan is generally contraindicated because the underlying susceptibility to bradykinin-mediated angioedema persists regardless of the ACEI withdrawal), patients of African American ancestry (who have a higher baseline incidence of bradykinin-mediated angioedema from renin-angiotensin system drugs), and patients who inadvertently receive or continue sacubitril-valsartan within 36 hours of their last ACEI dose during a class transition. The 36-hour washout requirement is based on the half-lives of commonly used ACEIs: enalaprilat (the active form of enalapril) has a half-life of approximately 11 hours, so 36 hours represents approximately 3.3 half-lives; lisinopril, which has a longer half-life of approximately 12 hours, also falls within this window. For patients transitioning from sacubitril-valsartan to an ACEI, the same 36-hour washout is required in the reverse direction because LBQ657 (active sacubitril metabolite) has a half-life of approximately 11–12 hours. Clinical monitoring for angioedema symptoms should be particularly attentive in the first 4–8 weeks of sacubitril-valsartan initiation, the period of highest risk during titration and steady-state establishment.8
In PARADIGM-HF, angioedema occurred in 0.45% of sacubitril-valsartan patients versus 0.24% of enalapril patients over a median follow-up of 27 months, a statistically significant difference. African American patients in the trial had higher rates in both arms (approximately 2.4% with sacubitril-valsartan versus 0.5% with enalapril), consistent with the known racial disparity in bradykinin-mediated angioedema susceptibility. No fatal angioedema events were reported in either arm during the trial. The trial excluded patients with prior ACEI-induced angioedema, so the risk in this higher-susceptibility population is not characterized by PARADIGM-HF and must be estimated from mechanistic considerations and case reports. Current prescribing guidance recommends avoiding sacubitril-valsartan in any patient with prior bradykinin-mediated angioedema regardless of the causative drug.
Beyond its established roles in HAE and ACEI-related adverse effects, bradykinin pharmacology intersects with several major disease areas where its pathophysiological contributions are increasingly well characterized. Chronic inflammatory pain, sepsis-associated hypotension, and the acute lung injury of COVID-19 all implicate the kallikrein-kinin system and represent potential targets for therapeutic intervention at multiple cascade steps. These emerging areas are presented as an orientation to active research directions rather than as established clinical pharmacology.
Bradykinin and its B1 and B2 receptors are prominent contributors to inflammatory hyperalgesia and neuropathic pain. Bradykinin is among the most potent endogenous algogens: direct application to exposed blister bases or injection into joint spaces produces immediate intense pain at nanomolar concentrations. In inflammatory states such as rheumatoid arthritis, osteoarthritis, and postoperative pain, bradykinin levels in synovial fluid and wound exudate are markedly elevated, and B2 receptor activation on peripheral sensory neurons contributes to sensitization through PKC-dependent phosphorylation of TRPV1 and TRPA1 channels, reducing their thermal activation thresholds and amplifying responses to other inflammatory mediators. The B1 receptor, upregulated by cytokines at sites of chronic inflammation, mediates sustained pain sensitization that does not desensitize, making it a particularly attractive target for chronic pain conditions. Several selective B1 and B2 receptor antagonists have been evaluated in clinical trials for conditions including diabetic peripheral neuropathy, osteoarthritis pain, and chronic respiratory disorders, with mixed results; the pharmacological challenge is that systemic bradykinin receptor blockade also disrupts beneficial cardiovascular effects of the kinin system, particularly the cardioprotective and vasodilatory effects mediated by endothelial B2 receptor activation.9
The kallikrein-kinin system is activated in sepsis and contributes to the hypotension and vascular leak of distributive septic shock through mechanisms that parallel but are distinct from the histaminergic response. Factor XII is activated by bacterial lipopolysaccharide (LPS) and by neutrophil extracellular traps (NETs) released during the inflammatory response, triggering plasma kallikrein generation and bradykinin release. Bradykinin-mediated vasodilation and vascular permeability increase at multiple microvascular beds contribute to the refractory hypotension of septic shock and are incompletely addressed by vasopressors that target the adrenergic and vasopressin systems. Pilot studies of icatibant and other B2 receptor antagonists in septic shock models showed transient improvement in hemodynamic parameters, but clinical translation has been hampered by the short half-life of available agents and the multiplicity of mediators driving septic hypotension. Factor XIIa inhibition (as explored with garadacimab and related agents) has theoretical appeal as an upstream intervention that would simultaneously block bradykinin generation and limit propagation through the coagulation and complement cascades that are co-activated in sepsis.10
The bradykinin hypothesis of COVID-19 pathophysiology, proposed in 2020 based on transcriptomic analysis of lung tissue from SARS-CoV-2-infected patients, proposes that the pulmonary edema, vascular leak, and severe hypoxemia of COVID-19 acute respiratory distress syndrome (ARDS) involve dysregulated bradykinin signaling. SARS-CoV-2 enters cells via the ACE2 receptor, downregulating ACE2 in the process; ACE2 (distinct from ACE) is a carboxypeptidase that degrades des-Arg9-bradykinin, the primary B1 receptor agonist. ACE2 depletion at the lung endothelium, combined with upregulation of ACE (which does not compensate for ACE2 loss because they act on different substrates), creates conditions for B1 receptor agonist accumulation, B1 receptor upregulation by the COVID-19 cytokine storm, and progressive vascular permeability increase at the pulmonary microvascular level. This mechanistic hypothesis generated interest in icatibant and other bradykinin-system modulators as potential COVID-19 treatments, but prospective clinical trials have not yet demonstrated clear benefit, and the hypothesis remains investigational rather than established clinical pharmacology.10
Future directions in kinin-targeted pharmacology include several promising modalities beyond the agents currently in clinical use. Tissue kallikrein inhibitors distinct from ecallantide (which targets plasma kallikrein) may provide analgesic and anti-inflammatory benefits at peripheral inflammatory sites without the systemic hemodynamic effects of systemic B2 receptor blockade. Long-acting depot formulations of icatibant and next-generation bradykinin receptor antagonists with improved oral bioavailability are in development for chronic conditions where parenteral administration is a barrier. Allosteric modulators of B1 and B2 receptors that selectively block pathological signaling pathways (such as PKC-TRPV1 coupling in pain) while preserving protective cardiovascular signaling represent a pharmacologically sophisticated approach to managing the therapeutic ratio. Finally, the integration of RNA interference therapies targeting HMWK, prekallikrein, or factor XII as long-acting prophylactic agents extends the gene-silencing approach already applied in HAE to other bradykinin-excess states. The field is expanding rapidly as the breadth of kallikrein-kinin system involvement in human disease becomes clearer.9
Baş M, Greve J, Stelter K, et al. A randomized trial of icatibant in ACE-inhibitor-induced angioedema. N Engl J Med. 2015;372(5):418–425.
doi:10.1056/NEJMoa1312524Lehmann A. Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery. Expert Opin Biol Ther. 2008;8(8):1187–1199.
doi:10.1517/14712598.8.8.1187Zuraw BL, Banerji A, Bernstein JA, et al. US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. J Allergy Clin Immunol Pract. 2013;1(5):458–467.
doi:10.1016/j.jaip.2013.07.002Banerji A, Riedl MA, Bernstein JA, et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA. 2018;320(20):2108–2121.
doi:10.1001/jama.2018.16162Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of hereditary angioedema: the 2017 revision and update. Allergy. 2018;73(8):1575–1596.
doi:10.1111/all.13384Longhurst HJ, Bork K. Hereditary angioedema: an update on causes, manifestations and treatment. Br J Hosp Med. 2019;80(7):391–398.
doi:10.12968/hmed.2019.80.7.391McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.
doi:10.1056/NEJMoa1409077Kostis WJ, Shetty M, Chowdhury YS, Kostis JB. ACE inhibitor-induced angioedema: a review. Curr Hypertens Rep. 2018;20(7):55.
doi:10.1007/s11906-018-0859-xMarceau F, Regoli D. Bradykinin receptor ligands: therapeutic perspectives. Nat Rev Drug Discov. 2004;3(10):845–852.
doi:10.1038/nrd1522van de Veerdonk FL, Netea MG, van Deuren M, et al. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. eLife. 2020;9:e57555.
doi:10.7554/eLife.57555